Animal Medicines Australia

animalmedicinesaustralia.org.au

Animal Medicines Australia Ltd (AMA) is the peak industry body representing the leaders of the animal health industry in Australia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

ZERION PHARMA AND HOVIONE EXTEND PARTNERSHIP TO COVER USE OF THE DISPERSOME® TECHNOLOGY PLATFORM IN NUTRACEUTICALS

Zerion Pharma and Hovione | August 24, 2022

news image

Hovione and Zerion Pharma announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology for the development and commercialization of cert...

Read More

BUSINESS INSIGHTS

HEALTH CANADA APPROVES IPSEN’S SOHONOS™ (PALOVAROTENE CAPSULES) AS THE FIRST APPROVED TREATMENT FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Ipsen | January 24, 2022

news image

Ipsen announced the Health Canada approval of Sohonos, an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.<...

Read More

RESEARCH

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

news image

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More

BUSINESS INSIGHTS

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

news image

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More
news image

PHARMA TECH

ZERION PHARMA AND HOVIONE EXTEND PARTNERSHIP TO COVER USE OF THE DISPERSOME® TECHNOLOGY PLATFORM IN NUTRACEUTICALS

Zerion Pharma and Hovione | August 24, 2022

Hovione and Zerion Pharma announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology for the development and commercialization of cert...

Read More
news image

BUSINESS INSIGHTS

HEALTH CANADA APPROVES IPSEN’S SOHONOS™ (PALOVAROTENE CAPSULES) AS THE FIRST APPROVED TREATMENT FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Ipsen | January 24, 2022

Ipsen announced the Health Canada approval of Sohonos, an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.<...

Read More
news image

RESEARCH

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More
news image

BUSINESS INSIGHTS

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More